Platelet activating factor receptor: Gateway for bacterial chronic airway infection in chronic obstructive pulmonary disease and potential therapeutic target

Expert Review of Respiratory Medicine

Volumn 9, Issue 4, 2015, Pages 473-485

  Shukla, Shakti Dhar ^a   Sohal, Sukhwinder Singh ^b   O'Toole, Ronan F ^a   Eapen, Mathew Suji ^a   Walters, Eugene Haydn ^a  

^a UNIVERSITY OF TASMANIA   (Australia)

^b UNIVERSITY OF TASMANIA   (Australia)

Author keywords

airway epithelium; bacterial adhesion; inhaled corticosteroids; PAFr antagonist; platelet activating factor receptor; pneumococcal infections

Indexed keywords

ADHESIN; CIGARETTE SMOKE; PHOSPHORYLCHOLINE; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR;

BACTERIAL CELL WALL; BACTERIAL COLONIZATION; BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; HAEMOPHILUS INFLUENZAE; HOST PATHOGEN INTERACTION; HUMAN; LOWER RESPIRATORY TRACT INFECTION; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR UPREGULATION; REVIEW; STREPTOCOCCUS PNEUMONIAE; COMPLICATION; LUNG; METABOLISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

BACTERIAL INFECTIONS; HUMANS; LUNG; PLATELET MEMBRANE GLYCOPROTEINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84937949101     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.1070673     Document Type: Review

References (120)

1. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2015. Available from: www.goldcopd.org/ [Last accessed 26 January 2015]
2. Halbert RJ, Natoli JL, Gano A, et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006;28(3): 523-32
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11):e442
4. Toelle BG, Xuan W, Bird TE, et al. Respiratory symptoms and illness in older Australians: the burden of obstructive lung disease (BOLD) study. Med J Aust 2013; 198(3):144-8
5. Habraken JM, ter Riet G, Gore JM, et al. Health-related quality of life in end-stage COPD and lung cancer patients. J Pain Symptom Manage 2009;37(6):973-81
6. Pasquale MK, Sun SX, Song F, et al. Impact of exacerbations on health care cost and resource utilization in chronic obstructive pulmonary disease patients with chronic bronchitis from a predominantly Medicare population. Int J Chron Obstruct Pulmon Dis 2012;7:757-64
7. van Dam van Isselt Ee F, Groenewegen-Sipkema KH, Spruit-van Eijk M, et al. Pain in patients with COPD: a systematic review and meta-analysis. BMJ Open 2014;4:9
8. Løkke A, Lange P, Scharling H, et al. Developing COPD: a 25 year follow up study of the general population. Thorax 2006;61(11):935-9
9. Lundback B, Lindberg A, Lindstrom M, et al. Not 15 but 50% of smokers develop COPD-Report from the obstructive lung disease in northern Sweden studies. Respir Med 2003;97:115-22
10. Kurmi OP, Lam KB, Ayres JG. Indoor air pollution and the lung in low-and medium-income countries. Eur Respir J 2012;40(1):239-54
11. Gordon SB, Bruce NG, Grigg J, et al. Respiratory risks from household air pollution in low and middle income countries. Lancet Respir Med 2014;2: 823-60
12. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010;182:693-718
13. Kodgule R, Salvi S. Exposure to biomass smoke as a cause for airway disease in women and children. Curr Opin Allergy Clin Immunol 2012;12:82-90
14. Kew KM and Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014;3:Cd010115
15. Vollenweider Daniela J, Jarrett H, Steurer-Stey Claudia A, et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;12:CD010257
16. Sohal SS, Ward C, Danial W, et al. Recent advances in understanding inflammation and remodeling in the airways in chronic obstructive pulmonary disease. Expert Rev Respir Med 2013;7:275-88
17. Sohal SS, Eapen MS, Shukla SS, et al. Novel insights into chronic obstructive pulmonary disease (COPD): an overview. EMJ Respir 2014;2:81-7
18. Hogg JC, McDonough JE, Sanchez PG, et al. Micro-Computed tomography measurements of peripheral lung pathology in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6:546-9
19. MacNee W, Tuder RM. New paradigms in the pathogenesis of chronic obstructive pulmonary disease I. Proc Am Thorac Soc 2009;6:527-31
20. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 2004;350:2645-53
21. Kim V, Rogers TJ, Criner GJ. New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;5:478-85
22. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007;176:454-9
23. Robinson J. Colonization and infection of the respiratory tract: What do we know? Paediatr Child Health 2004;9:21-4
24. Banerjee D, Khair OA, Honeybourne D. Impact of sputum bacteria on airway inflammation and health status in clinical stable COPD. Eur Respir J 2004;23:685-91
25. Cabello H, Torres A, Celis R, et al. Bacterial colonization of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study. Eur Respir J 1997;10:1137-44
26. Garcha DS, Thurston SJ, Patel AR, et al. Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD. Thorax 2012;67: 1075-80
27. Soler N, Ewig S, Torres A, et al. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease. Eur Respir J 1999;14:1015-22
28. Hill AT, Campbell EJ, Hill SL, et al. Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis. Am J Med 2000;109:288-95
29. Sethi S, Maloney J, Grove L, et al. Airway inflammation and bronchial bacterial colonization in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:991-8
30. Sethi S, Wrona C, Grant BJ, et al. Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;169:448-53
31. Weinreich UM, Korsgaard J. Bacterial colonisation of lower airways in health and chronic lung disease. Clin Respir J 2008;2: 116-22
32. Desai H, Eschberger K, Wrona C, et al. Bacterial colonization increases daily symptoms in patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014;11:303-9
33. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1618-23
34. Borg I, Rohde G, Loseke S, et al. Evaluation of a quantitative real-time PCR for the detection of respiratory syncytial virus in pulmonary diseases. Eur Respir J 2003;21:944-51
35. Falsey AR, Formica MA, Hennessey PA, et al. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;173:639-43
36. McManus TE, Marley AM, Baxter N, et al. Acute and latent adenovirus in COPD. Respir Med 2007;101:2084-90
37. Kasuga I, Hogg JC, Pare PD, et al. Role of genetic susceptibility to latent adenoviral infection and decreased lung function. Respir Med 2009;103:1672-80
38. Miravitlles M, Espinosa C, Fernandez-Laso E, et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1996;116:40-6
39. Rosell A, Monso E, Soler N, et al. Microbiologic determinants of exacerbation in chronic obstructive pulmonary disease. Arch Intern Med 2005;165:891-7
40. Sapey E, Stockley RA. COPD exacerbations. 2: aetiology. Thorax 2006;61: 250-8
41. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31
42. Patel IS, Seemungal TA, Wilks M, et al. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57: 759-64
43. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-52
44. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006;173:1114-21
45. Sethi S, Murphy TF. Bacterial infection in chronic obstructive pulmonary disease in 2000: a state-of-the-art review. Clin Microbiol Rev 2001;14:336-63
46. Mohan A, Chandra S, Agarwal D, et al. Prevalence of viral infection detected by PCR and RT-PCR in patients with acute exacerbation of COPD: a systematic review. Respirology 2010;15:536-42
47. Hershenson MB. Rhinovirus-induced exacerbations of asthma and COPD. Scientifica 2013;2013:405876
48. Fagon JY, Chastre J, Trouillet JL, et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990;142:1004-8
49. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998;157: 1498-505
50. Sethi S, Evans N, Grant BJ, et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002;347:465-71
51. Mallia P, Footitt J, Sotero R, et al. Rhinovirus infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:1117-24
52. Kline KA, Falker S, Dahlberg S, et al. Bacterial adhesins in host-microbe interactions. Cell Host Microbe 2009;5: 580-92
53. Pizarro-Cerda J, Cossart P. Bacterial adhesion and entry into host cells. Cell 2006;124:715-27
54. Grigg J. The platelet activating factor receptor: a new anti-infective target in respiratory disease? Thorax 2012;67:840-1
55. Cundell DR, Gerard NP, Gerard C, et al. Streptococcus pneumoniae anchor to activated human cells by the receptor for platelet-activating factor. Nature 1995;377: 435-8
56. Swords WE, Buscher BA, Ver Steeg Ii K, et al. Non-typeable Haemophilus influenzae adhere to and invade human bronchial epithelial cells via an interaction of lipooligosaccharide with the PAF receptor. Mol Microbiol 2000;37:13-27
57. Iovino F, Brouwer MC, van de Beek D, et al. Signalling or binding: the role of the platelet-activating factor receptor in invasive pneumococcal disease. Cell Microbiol 2013;15:870-81
58. Clementi C, Murphy T. Nontypeable Haemophilus influenzae invasion and persistence in the human respiratory tract. Front Cell Infect Microbiol. 2011;1:1
59. Shukla SD. Platelet-activating factor receptor and signal transduction mechanisms. Faseb j 1992;6:2296-301
60. Izumi T, Shimizu T. Platelet-activating factor receptor: gene expression and signal transduction. Biochim Biophys Acta 1995;1259:317-33
61. Nakamura M, Honda Z, Izumi T, et al. Molecular cloning and expression of platelet-activating factor receptor from human leukocytes. J Biol Chem 1991;266: 20400-5
62. Chen C, Xia SH, Chen H, et al. Therapy for acute pancreatitis with platelet-activating factor receptor antagonists. World J Gastroenterol 2008;14:4735-8
63. Cabellos C, MacIntyre DE, et al. Differing roles for platelet-activating factor during inflammation of the lung and subarachnoid space. The special case of Streptococcus pneumoniae. J Clin Invest 1992;90:612-18
64. Sagara H, Fukuda T, Okada T, et al. Theophylline at therapeutic concentration suppresses PAF-induced upregulation of Mac-1 on human eosinophils. Clin Exp Allergy 1996;26(Suppl 2):16-21
65. Soliman A, Michelsen KS, Karahashi H, et al. Platelet-activating factor induces TLR4 expression in intestinal epithelial cells: implication for the pathogenesis of necrotizing enterocolitis. PLoS One 2010; 5(10):e15044
66. Mosser DM. Receptors on phagocytic cells involved in microbial recognition. Immunol Ser 1994;60:99-114
67. Forsgren J, Samuelson A, Ahlin A, et al. Haemophilus influenzae resides and multiplies intracellularly in human adenoid tissue as demonstrated by in situ hybridization and bacterial viability assay. Infect Immun 1994;62:673-9
68. St Geme JW, Falkow S. Haemophilus influenzae adheres to and enters cultured human epithelial cells. Infect Immun 1990;58:4036-44
69. Berenson CS, Garlipp MA, Grove LJ, et al. Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease. J Infect Dis 2006;194: 1375-84
70. Berenson CS, Wrona CT, Grove LJ, et al. Impaired alveolar macrophage response to Haemophilus antigens in chronic obstructive lung disease. Am J Respir Crit Care Med 2006;174:31-40
71. Berenson CS, Kruzel RL, Eberhardt E, et al. Phagocytic dysfunction of human alveolar macrophages and severity of chronic obstructive pulmonary disease. J Infect Dis 2013;208:2036-45
72. Clark SE, Weiser JN. Microbial modulation of host immunity with the small molecule phosphorylcholine. Infect Immun 2013;81: 392-401
73. Thornton JA, Durick-Eder K, Tuomanen EI. Pneumococcal pathogenesis: "innate invasion" yet organ-specific damage. J Mol Med 2010;88:103-7
74. Van Eldere J, Slack MP, Ladhani S, et al. Non-typeable Haemophilus influenzae, an under-recognised pathogen. Lancet Infect Dis 2014;14:1281-92
75. Radin JN, Orihuela CJ, Murti G, et al. Beta-Arrestin 1 participates in platelet-activating factor receptor-mediated endocytosis of Streptococcus pneumoniae. Infect Immun 2005;73:7827-35
76. Ring A, Weiser JN, Tuomanen EI. Pneumococcal trafficking across the blood-brain barrier. Molecular analysis of a novel bidirectional pathway. J Clin Invest 1998;102:347-60
77. Iovino F, Molema G, Bijlsma JJE. Streptococcus pneumoniae Interacts with pIgR Expressed by the Brain Microvascular Endothelium but Does Not Co-Localize with PAF Receptor. PLoS One 2014;9(5): e97914
78. Ishizuka S, Yamaya M, Suzuki T, et al. Acid exposure stimulates the adherence of Streptococcus pneumoniae to cultured human airway epithelial cells: effects on platelet-activating factor receptor expression. Am J Respir Cell Mol Biol 2001;24:459-68
79. Mushtaq N, Ezzati M, Hall L, et al. Adhesion of Streptococcus pneumoniae to human airway epithelial cells exposed to urban particulate matter. J Allergy Clin Immunol 2011;127:1236-42.e1232
80. McCullers JA, Iverson AR, McKeon R, et al. The platelet activating factor receptor is not required for exacerbation of bacterial pneumonia following influenza. Scand J Infect Dis 2008;40:11-17
81. Shivshankar P, Boyd AR, Le Saux CJ, et al. Cellular senescence increases expression of bacterial ligands in the lungs and is positively correlated with increased susceptibility to pneumococcal pneumonia. Aging Cell 2011;10:798-806
82. Chao W, Olson MS. Platelet-activating factor: receptors and signal transduction. Biochem J 1993;292:617-29
83. Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest 1997;111:1266-72
84. Murphy TF. Respiratory infections caused by non-typeable Haemophilus influenzae. Curr Opin Infect Dis 2003;16:129-34
85. Geme JWS. Molecular and cellular determinants of non-typeable Haemophilus influenzae adherence and invasion. Cell Microbiol 2002;4:191-200
86. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N Engl J Med 2008;359:2355-65
87. Bandi V, Apicella MA, Mason E, et al. Nontypeable Haemophilus influenzae in the lower respiratory tract of patients with chronic bronchitis. Am J Respir Crit Care Med 2001;164:2114-19
88. Weiser JN, Shchepetov M, Chong ST. Decoration of lipopolysaccharide with phosphorylcholine: a phase-variable characteristic of Haemophilus influenzae. Infect Immun 1997;65:943-50
89. Clark SE, Snow J, Li J, et al. Phosphorylcholine allows for evasion of bactericidal antibody by Haemophilus influenzae. PLoS Pathog 2012;8:e1002521
90. Weiser JN, Pan N, McGowan KL, et al. Phosphorylcholine on the lipopolysaccharide of haemophilus influenzae contributes to persistence in the respiratory tract and sensitivity to serum killing mediated by C-reactive protein. J Exp Med 1998;187: 631-40
91. Schweda EK, Brisson JR, Alvelius G, et al. Characterization of the phosphocholine-substituted oligosaccharide in lipopolysaccharides of type b Haemophilus influenzae. Eur J Biochem 2000;267:3902-13
92. McCrea KW, Xie J, Marrs CF, et al. Prevalence of genetic differences in phosphorylcholine expression between nontypeable Haemophilus influenzae and Haemophilus haemolyticus. BMC Microbiol 2010;10:286
93. Weiser JN, Love JM, Moxon ER. The molecular mechanism of phase variation of H. influenzae lipopolysaccharide. Cell 1989;59:657-65
94. Michel V, Yuan Z, Ramsubir S, et al. Choline transport for phospholipid synthesis. Exp Biol Med 2006;231:490-504
95. Fan X, Pericone CD, Lysenko E, et al. Multiple mechanisms for choline transport and utilization in haemophilus influenzae. Mol Microbiol 2003;50:537-48
96. Craig JE, Cliffe A, Garnett K, et al. Survival of nontypeable haemophilus influenzae in macrophages. FEMS Microbiol Lett 2001;203:55-61
97. Fischer W, Behr T, Hartmann R, et al. Teichoic acid and lipoteichoic acid of streptococcus pneumoniae possess identical chain structures. A reinvestigation of teichoid acid (C polysaccharide). Eur J Biochem 1993;215:851-7
98. Swords WE, Ketterer MR, Shao J, et al. Binding of the non-typeable haemophilus influenzae lipooligosaccharide to the PAF receptor initiates host cell signalling. Cell Microbiol 2001;3:525-36
99. Rawlins EL, Hogan BL. Ciliated epithelial cell lifespan in the mouse trachea and lung. Am J Physiol Lung Cell Mol Physiol 2008;295:L231-4
100. Hinojosa E, Boyd AR, Orihuela CJ. Age-associated inflammation and toll-like receptor dysfunction prime the lungs for pneumococcal pneumonia. J Infect Dis 2009;200:546-54
101. Rijneveld AW, Weijer S, Florquin S, et al. Improved host defense against pneumococcal pneumonia in platelet-activating factor receptor-deficient mice. J Infect Dis 2004;189(4):711-16
102. van der Sluijs KF, van Elden LJ, Nijhuis M, et al. Involvement of the platelet-activating factor receptor in host defense against streptococcus pneumoniae during postinfluenza pneumonia. Am J Physiol Lung Cell Mol Physiol 2006;290(1):L194-9
103. Branger J, Wieland CW, Florquin S, et al. Platelet-activating factor receptor-deficient mice show an unaltered clearance of nontypeable Haemophilus influenzae from their respiratory tract. Shock 2004;22(6): 543-7
104. Shirasaki H, Nishikawa M, Adcock IM, et al. Expression of platelet-activating factor receptor mRNA in human and Guinea pig lung. Ame J Respir Cell Mol Bio 1994;10: 533-7
105. Grigg J, Walters H, Sohal SS, et al. Cigarette smoke and platelet-activating factor receptor dependent adhesion of Streptococcus pneumoniae to lower airway cells. Thorax 2012;67:908-13 protein level.
106. Suri R, Mallia P, Martin JE, et al. Bronchial platelet-activating factor receptor in chronic obstructive pulmonary disease. Respir Med 2014;108:898-904
107. Shukla SD, Sohal SS, Mahmood MQ, et al. Airway epithelial platelet-activating factor receptor expression is markedly upregulated in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014;9: 853-61
108. Ishizuka S, Yamaya M, Suzuki T, et al. Effects of rhinovirus infection on the adherence of Streptococcus pneumoniae to cultured human airway epithelial cells. J Infect Dis 2003;188:1928-39
109. Wang JH, Kwon HJ, Jang YJ. Rhinovirus enhances various bacterial adhesions to nasal epithelial cells simultaneously. Laryngoscope 2009;119:1406-11
110. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
111. Cates C. Inhaled corticosteroids in COPD: quantifying risks and benefits. Thorax 2013;68:499-500
112. Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009;34:641-7
113. Singh R, Mackay AJ, Patel AR, et al. Inflammatory thresholds and the species-specific effects of colonising bacteria in stable chronic obstructive pulmonary disease. Respir Res 2014;15:114
114. Hwang SB, Lam MH, Alberts AW, et al. Biochemical and pharmacological characterization of L-659,989: an extremely potent, selective and competitive receptor antagonist of platelet-activating factor. J Pharma Exp Therap 1988;246:534-41
115. Ponpipom MM, Hwang SB, Doebber TW, et al. (+/-)-trans-2-(3-Methoxyz5-methylsulfonyl-4-propoxyphenyl)-5-(3,4,5-trimethoxyphenyl)tetrahydrofuran (L-659,989), a novel, potent PAF receptor antagonist. Biochem Biophys Res Commun 1988;150:1213-20
116. Arnout J, van Hecken A, De Lepeleire I, et al. Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man. Br J Clin Pharmacol 1988;25:445-51
117. Adamus WS, Heuer HO, Meade CJ, et al. Inhibitory effects of the new PAF acether antagonist WEB-2086 on pharmacologic changes induced by PAF inhalation in human beings. Clin Pharm Therap 1990;47:456-62
118. Bandi V, Jakubowycz M, Kinyon C, et al. Infectious exacerbations of chronic obstructive pulmonary disease associated with respiratory viruses and non-typeable haemophilus influenzae. FEMS Immunol Med Microbiol 2003;37:69-75
119. Sethi S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon? Proc Am Thorac Soc 2004;1:109-14
120. Barbier M, Agusti A, Alberti S. Fluticasone propionate reduces bacterial airway epithelial invasion. Eur Respir J 2008;32(5):1283-8